A Case of Sodium Oxybate Treatment of Tardive Dyskinesia and Bipolar Disorder
J Clin Psychiatry 2008;69(5):862 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: Sodium oxybate is increasingly being used off-label
to treat the fibromyalgia syndrome defined by pain, fatigue,
nonrefreshing sleep, and fluency loss. This compound has a
complicated mechanism of action with agonist binding on
?-aminobutyric acid (GABA)-B receptor, agonist binding on the
?-hydroxybutyrate (GHB) receptor, and possible stoichiometric
signaling effects as an intermediary in GABA and glutamate
metabolism. Its clinical effect is a profound increase in the duration
of stage III and IV slow wave sleep. This case describes
a profound effect of oxybate on bipolar disorder and tardive
dyskinesia presenting jointly with fibromyalgia.